Skip to main content
. 2016 Oct 4;7(51):84736–84747. doi: 10.18632/oncotarget.12450

Figure 2. Pharmacokinetic profile of oral ridaforolimus in pediatric patients.

Figure 2

A. Mean (± SD) blood concentration of ridaforolimus following oral dosing at 22, 28, and 33 mg/m2 once daily for 5 days per week of a 28-day cycle in pediatric patients. Top panel: linear scale; bottom panel: semi-log scale. B. Exposure (AUC0–24h) relative to actual dose of oral ridaforolimus (calculated based on body surface area) in pediatric patients.

HHS Vulnerability Disclosure